
    
      This is a phase IB, open-label, non-randomized, dose-escalation study that will be conducted
      in sequential cohorts of patients. Three patients per each cohort are planned.

      Patients, with advanced or metastatic solid tumor not amenable of standard therapy will be
      enrolled.
    
  